Emergent BioSolutions (NYSE:EBS) Downgraded by StockNews.com to “Hold”

Emergent BioSolutions (NYSE:EBS) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts also recently issued reports on EBS. Rodman & Renshaw reissued a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark increased their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Trading Down 1.8 %

NYSE EBS opened at $8.27 on Friday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The stock has a market capitalization of $448.10 million, a P/E ratio of -2.02 and a beta of 1.59. Emergent BioSolutions has a 52-week low of $1.42 and a 52-week high of $15.10. The firm has a 50-day moving average price of $9.23 and a 200 day moving average price of $8.84.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in EBS. Federated Hermes Inc. lifted its position in shares of Emergent BioSolutions by 1,314.0% during the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after acquiring an additional 253,960 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in Emergent BioSolutions in the 3rd quarter valued at approximately $1,547,000. Headlands Technologies LLC acquired a new position in Emergent BioSolutions during the second quarter worth $969,000. Oak Hill Advisors LP purchased a new stake in Emergent BioSolutions during the third quarter worth $9,296,000. Finally, Assenagon Asset Management S.A. boosted its position in Emergent BioSolutions by 74.5% during the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after purchasing an additional 316,700 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.